オプションチェーンは、GE HealthCare Techsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、GE HealthCare Techsの市場センチメントを評価します。.

GE HealthCare Techs (NASDAQ:GEHC) 株価情報, オプションチェーン

GE HealthCare Techs

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Technologies Inc

GE HEALTHCARE TECHNOLOGIES ORD

WIIM

JFBR

Jeffs' Brands shares are trading higher after the company announced it entered into a non-binding letter of intent for the sale of a subsidiary valued at $13.5 million.

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent.

Earnings

Earnings Beats

News

DSGN

Design Therapeutics Q3 2024 GAAP EPS $(0.23) Beats $(0.31) Estimate

Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.84 million which missed the analyst consensus estimate of $71.74 million by 1.26 percent. This is a 13.01 percent increase over sales of $62.68 million the same period last year.

Earnings Misses

CTLP

Cantaloupe Q1 EPS $0.04, Inline, Sales $70.84M Miss $71.74M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidentiv.com&amp;esheet=54148677&amp;newsitemid=20241107448252&amp;lan=en-US&amp;anchor=Identiv%2C+Inc&amp;index=1&amp;md5=7038f21113fe10c77c0bb35b935bf53b">Identiv, Inc</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidentiv.com&amp;esheet=54148677&amp;newsitemid=20241107448252&amp;lan=en-US&amp;anchor=.&amp;index=2&amp;md5=99b6eaee914a3599ca5133f57d2023b0">.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>), a global leader in RFID-enabled Internet of Things (IoT) solutions, today announced that its Board of Directors has authorized a stock repurchase program for up to $10 million of its common stock. The Company also announced its Board of Directors intends to propose changes to the Company's corporate governance policies in advance of the 2025 annual meeting of stockholders.

Buybacks

INVE

Identiv Announces $10M Stock Repurchase Program

Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) .

Guidance

PBPB

Potbelly 4Q 24 Guidance: Same Store Sales -2.5% to -0.5%, Adj. EBITDA $7M-$8M.

PACB

Pacific Biosciences Says On The Path To Return To Growth In 2025 And Beyond

Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.39 by 30.77 percent. The company reported quarterly sales of $86.101 million which missed the analyst consensus estimate of $111.128 million by 22.52 percent. This is a 15.09 percent decrease over sales of $101.397 million the same period last year.

ADEA

Adeia Q3 2024 Adj. EPS $0.27 Misses $0.39 Estimate, Sales $86.101M Miss $111.128M Estimate

Block Sees FY24 Adj. EBITDA $2.90B

SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $888.72 thousand which missed the analyst consensus estimate of $1.10 million by 19.21 percent. This is a 39.38 percent decrease over sales of $1.47 million the same period last year.

SSSS

SuRo Capital Q3 EPS $(0.14) Beats $(0.15) Estimate, Sales $888.72K Miss $1.10M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ringcentral.com%2F&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=RingCentral%2C+Inc.+%28NYSE%3A+RNG%29&amp;index=1&amp;md5=c2845406a58e8205490c85feb96a44fc">RingCentral, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>), a global leader in AI-powered trusted business communications for companies of all sizes, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=Verint%26%23174%3B+%28NASDAQ%3A+VRNT%29&amp;index=2&amp;md5=ff2052d631e7be32c2f061531c2594a7">Verint&#xAE; (NASDAQ:</a><a href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), a leader in CX automation, today announced a strategic partnership to provide <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ringcentral.com%2Fringcx.html&amp;esheet=54149025&amp;newsitemid=20241107126443&amp;lan=en-US&amp;anchor=RingCX&amp;index=3&amp;md5=9b55f66ae5a500a88ea806afa45513bd">RingCX</a>&#x2122; customers access to best-in-class workforce engagement management (WEM) and CX automation. Through this partnership, RingCX customers will have more choice and be able to leverage Verint's leading WEM and CX automation solutions, which complement RingCentral's native AI capabilities, to enhance employee productivity and improve customer experiences, ultimately driving competitive advantage and operational efficiency.

VRNT

RingCentral And Verint Announce Strategic Partnership To Bring AI-Powered Workforce Engagement Management And CX Automation To RingCX Customers

Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. The company reported quarterly sales of $20.16 million which missed the analyst consensus estimate of $20.40 million by 1.18 percent. This is a 0.74 percent increase over sales of $20.01 million the same period last year.

SGHT

Sight Sciences Q3 2024 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $20.16M Miss $20.40M Estimate

Block Sees Q4 Adj. EBITDA $725M

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) raises FY2024 sales outlook from $325.00 million-330.00 million to $329.00 million-331.00 million.

INGN

Inogen Raises FY2024 Sales Guidance from $325.00M-330.00M to $329.00M-331.00M

NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. The company reported quarterly sales of $475.00 thousand which missed the analyst consensus estimate of $3.14 million by 84.87 percent. This is a 93.17 percent decrease over sales of $6.95 million the same period last year.

NuScale Power Q3 2024 GAAP EPS $(0.18) Misses $(0.15) Estimate, Sales $475.00K Miss $3.14M Estimate

Mettler-Toledo Sees FY24 Adj. EPS $40.35-$40.50 Vs $40.38 Estimate

Opendoor Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) sees Q4 sales of $925.000 million-975.000 million vs $1.20 billion estimate.

OPEN

Opendoor Technologies Sees Q4 Sales $925.000M-975.000M vs $1.20B Est

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. The company reported quarterly sales of $173.600 million which missed the analyst consensus estimate of $181.525 million by 4.37 percent. This is a 2.80 percent decrease over sales of $178.600 million the same period last year.

OPKO Health Q3 2024 Adj. EPS $(0.09), Inline, Sales $173.600M Miss $181.525M Estimate

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) affirms FY2025 sales outlook from $490.00 million-500.00 million to $490.00 million-500.00 million.

BARK

BARK Affirms FY2025 Sales Guidance from $490.00M-500.00M to $490.00M-500.00M

P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.20 by 30 percent. The company reported quarterly sales of $74.243 million which beat the analyst consensus estimate of $66.972 million by 10.86 percent. This is a 25.96 percent increase over sales of $58.942 million the same period last year.

P10 Q3 2024 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $74.243M Beat $66.972M Estimate

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) sees Q3 sales of $123.000 million-126.000 million vs $128.27 million estimate.

BARK Sees Q3 Sales $123.000M-126.000M vs $128.27M Est

GE HealthCare Technologies Inc. (GEHC) Q3 2024 Earnings Call Transcript

From Spin-Off To Standout: GE HealthCare Is Pretty Impressive

GE Healthcare Technologies Inc (GEHC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst P...

Hold Rating on GE Healthcare Due to Stagnant Demand and Uncertain Growth Prospects

Piper Sandler raised the firm's price target on GE HealthCare (GEHC) to $97 from $95 and keeps an Overweight rating on the shares. The firm notes G...

GE HealthCare price target raised to $97 from $95 at Piper Sandler

Oppenheimer analyst Suraj Kalia maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) today and set a price target of ...

Oppenheimer Reaffirms Their Buy Rating on GE Healthcare Technologies Inc (GEHC)

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) today. The company's shares cl...

Stifel Nicolaus Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)

Healthcare Investing Finding Growth Beyond Pharmaceuticals

BTIG analyst Ryan Zimmerman maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of ...

BTIG Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)

GE HealthCare: Light Up With Growth Indicators In Medical Tech, While Undervalued

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report), with a pri...

Promising Outlook for GE Healthcare: Buy Rating Backed by Innovation, Growth, and Margin Improvements

AGNG

ARKG

BMED

CNCR

EDOC

FHLC

FTXH

GEHC

GNOM

HART

HELX

HTEC

IBBQ

IDNA

IDXX

ISRG

LABU

MDEV

PILL

PINK

PSCH

RSPH

SBIO

UTHR

VEEV

WDNA

Press Releases

GE HealthCare to announce third quarter 2024 results on October 30, 2024

GE HealthCare Accelerates Artificial Intelligence Adoption With New Offering to Advance Enterprise Imaging

GE HealthCare introduces easy-to-use, easy-to-learn, easy-to-diagnose Versana Premier multi-purpose ultrasound system

A New Theranostics Center of Excellence in Europe: GE HealthCare and University Medicine Essen Collaborate to Advance Theranostics and Personalized Medicine

Comments

GE HealthCare Techs

GE HealthCare Techs (GEHC) オプション

GE HealthCare Techs (NASDAQ:GEHC) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル